{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15(5)"],"submitter":["Boettcher M"],"funding":["Bayer","Merck","Merck Sharp and Dohme"],"pubmed_abstract":["Vericiguat was developed for the treatment of symptomatic chronic heart failure (HF) in adult patients with reduced ejection fraction who are stabilized after a recent decompensation event. Guidelines recommend long-acting nitrates, such as isosorbide mononitrate, for angina prophylaxis in chronic coronary syndromes (CCS), common comorbidities in HF. This study evaluated safety, tolerability, and the pharmacodynamic (PD) interaction between co-administered vericiguat and isosorbide mononitrate in patients with CCS. In this phase Ib, double-blind, multicenter study, patients were randomized 2:1 to receive vericiguat plus isosorbide mononitrate (n = 28) or placebo plus isosorbide mononitrate (n = 13). Isosorbide mononitrate was uptitrated to a stable dose of 60 mg once daily, followed by co-"],"journal":["Clinical and translational science"],"pagination":["1204-1214"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9099120"],"repository":["biostudies-literature"],"pubmed_title":["Vericiguat in combination with isosorbide mononitrate in patients with chronic coronary syndromes: The randomized, phase Ib, VISOR study."],"pmcid":["PMC9099120"],"pubmed_authors":["Dungen HD","Schulz-Burck D","Hung J","Mikus G","Werner N","Boettcher M","Karakas M","Gerrits M","Besche N","Donath F","Becker C","Trenk D"],"additional_accession":[]},"is_claimable":false,"name":"Vericiguat in combination with isosorbide mononitrate in patients with chronic coronary syndromes: The randomized, phase Ib, VISOR study.","description":"Vericiguat was developed for the treatment of symptomatic chronic heart failure (HF) in adult patients with reduced ejection fraction who are stabilized after a recent decompensation event. Guidelines recommend long-acting nitrates, such as isosorbide mononitrate, for angina prophylaxis in chronic coronary syndromes (CCS), common comorbidities in HF. This study evaluated safety, tolerability, and the pharmacodynamic (PD) interaction between co-administered vericiguat and isosorbide mononitrate in patients with CCS. In this phase Ib, double-blind, multicenter study, patients were randomized 2:1 to receive vericiguat plus isosorbide mononitrate (n = 28) or placebo plus isosorbide mononitrate (n = 13). Isosorbide mononitrate was uptitrated to a stable dose of 60 mg once daily, followed by co-","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2026-05-09T23:39:02.78Z","creation":"2025-04-04T19:33:03.672Z"},"accession":"S-EPMC9099120","cross_references":{"pubmed":["35299288"],"doi":["10.1111/cts.13238"]}}